NCT02323880 2025-01-14
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Children's Oncology Group
Phase 1 Completed
Clinical Trials
4 trialsNCT06573151 2024-08-27
Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL
Ruijin Hospital
Phase 2 Not yet recruiting
NCT05852028 2023-05-10
A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma
Ruijin Hospital
Unknown
NCT02741388 2021-12-07
SELINDA
The Lymphoma Academic Research Organisation
Phase 1 Completed